References
  1. Chaplin DD. Overview of the immune response. J Allergy Clin Immunol 2010 ;125(2): S3-23
  2. Bonilla FA, Oettgen HC. Adaptive immunity. J Allergy Clin Immunol 2010 ;125:S33-S40
  3. Wang L, Wang FS. Human autoimmune diseases. A comprehensive update. J Intern Med 2015 ;278(4=:369-95
  4. Sjoberg AP, Trouw LA, Blom AM. Complement activation and inhibition: a delicate balance. Trends Immunol 2009 ;30:83-90
  5. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol 2010 ;125:s182-S194
  6. Melvold RW,Sticca RP. Basic and tumour immunology: a review. Surgical Oncology Clinics 2007 ; 16(4):711-735
  7. Thapa P. The role of the thymus in the immune response. Thor Surg Clin 2019; 29(2):123-31
  8. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007 ;449:819-826
  9. Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections. J Immunol 2008; 181:3733-3739
  10. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003 ;3:23-3S
  11. Gaikwad S, Agrawal MY, Kaushik I, Ramachandran S, Srivastava SK. Immune checkpoint proteins: signalling mechanisms and molecular interactions in cancer immunotherapy. Semin Cancer Biol 2022 ;86(Pt 33): 137-150
  12. Barre- Sinoussi F, Chermann JC, Rey F. Isolation of T- lymphotropic retrovirus from a patient at risk of AIDS. Science 1983 ;220: 868-870
  13. Shindiaina P, Ahmed EH, Mozhenkova A, Abebe T, Baiocchi RA. Immunology of EBV-related lymphoproliferative disease in HIV- positive individuals. Front Oncol 2020 ;10:-2020
  14. Weledji EP, Ngowe MN, Abba JS. Burkitt’s lymphoma masquerading as appendicitis. World J of Surgical Oncology 2014 ;12:187
  15. Gallo RC, Salahuddin SZ, Popovic M. Human T- lymphotropic retrovirus, HTLV III, isolated from AIDS. Science 1983 ;220:868-870
  16. Balato A. Untmaz D, Gaspari AA. Natural killer T cells: an unconventional T –cell subset with diverse effector and regulatory functions. J Invest Dermatol 2009 ;129:1628-1642
  17. Kennedy AD, DeLeo FR. Neutrophil apoptosis and the resolution of infection. Immunol Res 2009 ;43:25-61
  18. Minai-Fleminger Y, Levi-Schaffer F. Mast cells and eosinophils: the two key effector cells in allergic inflammation-. Inflamm Res 2009 ;58:631-638
  19. Schroeder HW, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010 ;125:S41-S52
  20. Chaudhuri J, Basu U, Zarrin A, et al. Evolution of the immunoglobulin heavy chain class switch recombination mechanism. Adv Immunol 2007 ; 94:157-214
  21. Tangye SG, Tarlington DM. Memory B cells effectors of long-lived immune responses. Eur J Immunol 2009 ;39:2065-2075
  22. Thomas LR, Cobb RM, Oltz EM. Dynamic regulation of antigen receptor gene assembly. Adv Exp Med Biol 2009 ;650:103-115
  23. Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 2007;8:1295-1301
  24. Allen CD, Okada T, Cyster JQ. Germinal-centre organization and cellular dynamics. Immunity 2007 ;27:190-202
  25. Prausnitz C. In: Gell PGH, Coombs RRA, editors. Clinical aspects of immunology. Oxford: Blackwell; 1962 . P.808-816):160-169
  26. Dispenza MC. Classification of hypersensitivity reactions.Allergy Asthma Proc. 2019 ;40(6);470-473
  27. Galli F, Aguilera JV, Palermo B, et al. Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy.J of Exp Clin cancer research 2020 ;39:89
  28. Martin-liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J. The expanding role of immunotherapy. Cancer Treatment Review 2017 ;54: 74-86
  29. Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti- cancer therapies. J of experimental clinical cancer research 2019 ;38(1):156
  30. Al-Hadidi A, Lum LG, Sukari A, Nagasaka M, et al. Cancer immunology and immunotherapy. Anticancer research 2016 ;36(11):5593-5606
  31. Jin S, Sun Y, Liang X, et al. Emerging new therapeutic antibody derivatives for cancer treatment. Sig Transduct Target Ther 2022 ;7.39
  32. Kaja SL, Kiran SVNS, et al. A review on tumour immunology. J of Oncological Sciences 201 7;9(1):7
  33. De Visser KE, Eichten A, Coussens LM. Paradoxical roles of immune system during cancer development. Nature reviews cancer 2006 ;6(1): 24
  34. Scholm J, Gulley JL, Arlen PM. Role of vaccine therapy in cancer: biology and practice. Curr Oncol 2007 ;14(6).238-245
  35. Ngu VA, Tangwa GB. Effective vaccine against and immunotherapy of the HIV: Scientific Report and Ethical Considerations from Cameroon.J of the Cameroon Acad of Sciences 2015 ;12(2):77-84
  36. Rojas LA, Sethna Z, Soares KC, et al. Personalised RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 2023 ;618:144-150
  37. Zhang Y, Choi M. Immune therapy in pancreatic cancer. Now and the future? Rev Recent Clin Trials 2015 ;10:317-25
  38. Tanemura M, Miyosji E, NaganoH, et al. Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/ natural anti-Gal antibody reaction. World J Gastroenterol 2015 ;4011396-410
  39. Colignon A, Perles-Barbacaru AT, Robert S et al. A pancreatic tumour-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination. Oncotarget 2015 :6:23462-79
Legend
Table 1. Receptors and surface antigens present on T and B lymphocytes
Table 1. Receptors and surface antigens present on T and B lymphocytes